RxDoctor Payments DataLook up a doctor →

Gregory Connor, MD

Neurology · Tulsa, OKNPI 1437143534

Payments from drug & device makers

$446,845in general payments, 2019–2025

Across 589 payments — averaging $758.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SK Life Science, Inc.$440K
  • UCB, Inc.$4K
  • UCB SA$2K
  • Teva Pharmaceuticals USA, Inc.$313
  • Biohaven Pharmaceuticals, Inc.$125
  • Amgen$125
  • plus $472 from 4 others

What the payments were for

  • Consulting fees$30,0557%
  • Speaking & faculty fees$364,41082%
  • Travel & lodging$36,9818%
  • Food & beverage$12,8313%
  • Education$1990%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$446,845 in reported general payments places this provider in the 90th percentile of 152 neurology providers in Oklahoma.

See all neurology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$147,823
Medicare patients
745
Services billed
2,049

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XcopriCenobamate780$1,108,753
BriviactBrivaracetam414$639,569
Vigabatrin13$241,923
EpidiolexCannabidiol (Cbd)38$157,300
Lacosamide1,080$119,275
FycompaPerampanel77$90,982
ValtocoDiazepam26$54,712
ZonegranZonisamide12$46,799
Levetiracetam988$30,959
Tetrabenazine13$21,241
NayzilamMidazolam15$20,041
Topiramate1,461$18,784
Emgality PenGalcanezumab-Gnlm23$17,646
Nurtec OdtRimegepant Sulfate14$16,005
Rufinamide15$15,011

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SK Life Science, Inc.Xcopri$440,358$1,108,753780 claims
UCB, Inc.Briviact, Nayzilam$3,665$659,610429 claims
Neurelis, Inc.Valtoco$114$54,71226 claims
PfizerNurtec Odt$109$16,00514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 152 neurology providers in Oklahoma.

Other neurology in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →